Market research
ZBIO Zenas BioPharma, Inc. Common Stock
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 2B
- P/E ratio
- Not available
- Analyst target
- 47
- Dividend yield
- Not available
- Beta
- Not available
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US98937L1052
- Market cap
- 2B
- P/E ratio
- Not available
- Analyst target
- 47
- Dividend yield
- Not available
- Beta
- Not available
About
About Zenas BioPharma, Inc. Common Stock
Zenas BioPharma, Inc., a clinical-stage biopharma company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and Fc"RIIb for the treatment of various I&I diseases and various indications, including immunoglobulin G4-related disease, multiple sclerosis, and systemic lupus erythematosus. The company develops ZB002, an anti-TNFa monoclonal antibody; ZB004, a CTLA-4-Ig fusion protein designed to have an extended half-life versus; and ZB001, an anti-IGF-1R monoclonal antibody. The company was formerly known as Zenas BioPharma (Cayman) Limited and changed its name to Zenas BioPharma, Inc. in August 2023. The company was incorporated in 2019 and is headquartered in Waltham, Massachusetts.
Visit company websiteCommunity
Investor discussion
0 comments
Sign in to join the ZBIO discussion.
No comments yet
Start a focused discussion about ZBIO.